- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | enGene Appoints Michael Heffernan As Board Chairman Ahead Of Planned BLA Filing For Bladder Cancer Therapy | 2 | pulse2.com | ||
| 16.07. | enGene appoints Michael Heffernan as board chairman | 1 | Investing.com | ||
| 16.07. | enGene: Michael Heffernan übernimmt Vorsitz des Verwaltungsrats | 1 | Investing.com Deutsch | ||
| 16.07. | enGene Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ENGENE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Morgan Stanley cuts Engene stock rating on reduced sales outlook | 2 | Investing.com | ||
| 18.06. | Engene: Morgan Stanley senkt Rating wegen schwächerer Umsatzaussichten | 2 | Investing.com Deutsch | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | 4 | BioPharma Dive | ||
| 16.06. | H.C. Wainwright cuts Engene stock price target on clinical setbacks | 1 | Investing.com | ||
| 15.06. | enGene Holdings GAAP EPS of $0.43 | 1 | Seeking Alpha | ||
| 15.06. | enGene Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.06. | enGene Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Analysts cut enGene cancer sales forecast after updated data widen gap to J&J | 13 | FierceBiotech | ||
| 08.05. | Citizens downgrades Engene Holdings stock rating on weaker trial data | 2 | Investing.com | ||
| 08.05. | Citizens stuft Engene Holdings-Aktie nach schwachen Studiendaten ab | 19 | Investing.com Deutsch | ||
| 08.05. | Raymond James downgrades Engene Holdings stock rating on trial results | 2 | Investing.com | ||
| 08.05. | Piper Sandler cuts Engene Holdings stock rating on trial concerns | 1 | Investing.com | ||
| 08.05. | Engene Holdings: Raymond James stuft Aktie nach enttäuschenden Studienergebnissen herab | 9 | Investing.com Deutsch | ||
| 08.05. | Piper Sandler stuft Engene Holdings wegen Bedenken bei klinischer Studie ab | 6 | Investing.com Deutsch | ||
| 08.05. | Engene stock rating cut to Perform by Oppenheimer on trial data | 2 | Investing.com | ||
| 08.05. | Guggenheim stuft Engene-Aktie nach schwachen Studiendaten herab | 8 | Investing.com Deutsch |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,65 | -0,43 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| AMGEN | 360,40 | -0,28 % | Guggenheim raises Amgen stock price target to $388 on strong quarter | ||
| NOVAVAX | 6,840 | +0,15 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,72 | -0,46 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,360 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| CLINUVEL | 5,896 | +1,13 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,200 | +1,17 % | Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? | ||
| INTELLIA THERAPEUTICS | 10,500 | +0,77 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 47,355 | -0,72 % | Opening Bell: Wall Street auf Erholungskurs; Alphabet, SpaceX, Intel, Tempus AI, NextEra Energy ... | Die US-Börsen wagen am Freitag wohl einen Stabilisierungsversuch nach dem erneuten Rückschlag am Vortag. Besonders galt dies für den Leitindex Dow Jones Industrial, der eine Stunde vor dem Auftakt vom... ► Artikel lesen | |
| EDITAS MEDICINE | 2,490 | +2,05 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,310 | -2,67 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 60,16 | +0,77 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| ABIVAX | 111,00 | 0,00 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| EXELIXIS | 46,480 | +1,26 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M | ||
| SAREPTA THERAPEUTICS | 14,260 | -4,30 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated |
ENGENE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENGENE THERAPEUTICS INC finden Sie auf Wallstreet Online.